- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00977496
Development of a Probiotic Strategy to Prevent or Eliminate Nasal Colonization With S. Aureus
March 17, 2015 updated by: Tufts Medical Center
Development of a Probiotic Strategy to Prevent or Eliminate Nasal Colonization With S Aureus
The goal of this study is characterize the changes in bacterial diversity of the nares of hemodialysis patients.
Another goal is to determine when hemodialysis patients become colonized with the bacteria Staphylococcus aureus, as nasal colonization with S. aureus is a major risk factor for invasive infection in hemodialysis patients.
Fifteen subjects will be recruited into the study.
Nasal swabs will be collected every month for six months or until one month after S. aureus colonization in order to determine any changes in the bacterial communities of the nose.
Clinical data will also be collected to evaluate the possible influence of external factors on changes in the microbial communities in the patients' noses.
This study will provide preliminary data on whether oral- and/or nasal-administered probiotics can eliminate nasal carriage of S. aureus.
Study Overview
Study Type
Observational
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients from the Boston Dialysis Center Inc outpatient hemodialysis clinic of Tufts Medical Center.
Description
Inclusion Criteria:
- Male and female subjects aged 18 years or older
- On a stable hemodialysis schedule three times a week at Tufts Medical Center outpatient hemodialysis unit
- Able to speak English, Spanish, Cantonese, or Mandarin (One of these languages is spoken by >95% of our hemodialysis population)
- Provides informed consent to participate in the study
- No plans to be absent from the dialysis unit in the next 6 months
- Willingness to report on adverse events during the study period
Exclusion Criteria:
- Patients in which hemodialysis was indicated for acute renal failure secondary to septic shock, acute tubular necrosis, or other condition which is felt to be temporary or secondary to a life threatening illness or likelihood of hemodialysis for less than 6 months.
- Treatment with systemic anti-staphylococcal antibiotic therapy within 30 days prior to enrollment or planned use of topical mupirocin applied to the nares
- Receiving peritoneal dialysis (concordance between the colonizing and infecting strain is not as high as in the hemodialysis population (105))
- Absolute neutrophil count less than 500/mm3 or anticipated fall in neutrophil count < 500/mm3 (e.g. as a result of recent chemotherapy)
- Bleeding diathesis such as platelets count less than 20 or INR >4 within the last 30 days
- On immunosuppressive therapy
- Anticipated renal transplant during the next 6 months
- Evidence of active bowel leak, acute abdomen or colitis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Nasal Swab
New chronic hemodialysis patients with no evidence of nasal carriage of Staphylococcus aureus from Boston Dialysis Center Inc., the outpatient hemodialysis clinic of Tufts Medical Center
|
Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To describe the clinical variables that may be associated with the acquisition of S aureus nasal colonization, over a six-month period.
Time Frame: Monthly for 6 months or monthly until 1 month after positive nasal swab for S aureus
|
Monthly for 6 months or monthly until 1 month after positive nasal swab for S aureus
|
To refine and test the feasibility of using non culture-based methods to study the microbial ecology and bacterial diversity of the anterior nares in patients starting hemodialysis using 16sRNA sequence analysis.
Time Frame: Monthly for 6 months or monthly until 1 month after positive nasal swab for S aureus
|
Monthly for 6 months or monthly until 1 month after positive nasal swab for S aureus
|
To explore changes in bacterial diversity in the anterior nares over a six-month period and in conjunction with S aureus colonization.
Time Frame: Monthly for 6 months or monthly until 1 month after positive nasal swab for S aureus
|
Monthly for 6 months or monthly until 1 month after positive nasal swab for S aureus
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Study Registration Dates
First Submitted
September 14, 2009
First Submitted That Met QC Criteria
September 14, 2009
First Posted (Estimate)
September 15, 2009
Study Record Updates
Last Update Posted (Estimate)
March 18, 2015
Last Update Submitted That Met QC Criteria
March 17, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 8784 (CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis
-
National Taiwan University HospitalCompletedHemodialysis Complication | Hemodialysis-Induced SymptomTaiwan
-
Ain Shams UniversityCompleted
-
Imperial College Healthcare NHS TrustCompletedHemodialysisUnited Kingdom
-
Lawson Health Research InstituteUnknown
-
Federico II UniversityUnknown
-
Hospital Clinic of BarcelonaSocietat Catalana de NefrologiaCompleted
-
Brigham and Women's HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Angion Biomedica CorpNucleus Network LtdNot yet recruitingHemodialysisUnited States
-
Assistance Publique - Hôpitaux de ParisRecruiting
Clinical Trials on Nasal Swab
-
University of Colorado, DenverGlaxoSmithKlineCompletedFever | Influenza | Otitis Media | Lower Resp Tract Infection | Encephalitic Infection | Myositis ViralUnited States
-
Rigshospitalet, DenmarkRecruitingCOVID-19 | Influenza | RSV InfectionDenmark
-
LumiraDx UK LimitedActive, not recruitingCOVID-19United States
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Assistance Publique Hopitaux De MarseilleCompletedInfective PericarditisFrance
-
Rush University Medical CenterCompletedParkinson DiseaseUnited States
-
Institut PasteurRecruiting
-
University Hospital, CaenCompletedMicrobial Colonization | Neonatal Infection | Viral InfectionFrance
-
Public Health EnglandCompletedImmunization; InfectionUnited Kingdom
-
LumiraDx UK LimitedActive, not recruiting